Clinical trials: ADPKD, active
Autosomal Dominant Polycystic Kidney
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
The proposed research is a pilot study assessing kidney oxidative metabolism and insulin sensitivity after a 2-year weight loss intervention in those with autosomal dominant polycystic kidney disease who are overweight or obese.
- Trial name
- EXPLORE (NCT06496542)
- Testing
- Daily caloric restriction, Standard advice control
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults
The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants
- Trial name
- NCT07470177
- Testing
- JMKX003142 tablets
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jemincare
Autosomal Dominant Polycystic Kidney Disease
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
This study will investigate if a medication (metformin) widely used in the treatment of diabetes could be re-purposed for the treatment of patients with a diagnosis of early stage ADPKD to slow the rate of kidney function…
- Trial name
- NCT04939935
- Testing
- Metformin XR, Control
- Where
- 49 sites in Australia, New Zealand and 1 more
- Volunteers
- 1,174 people
- Sponsor
- The University of Queensland
Autosomal Dominant Polycystic Kidney Disease
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
The purpose of this study is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of…
- Trial name
- HCY (NCT05193981)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository
This study will analyze the germline and somatic mutations underlying the development of ADPKD in order to better understand the genetic mechanism responsible for the cystic transformation.
- Trial name
- ADPKD (NCT03901521)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Weill Medical College of Cornell University
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.
- Trial name
- PKD-KETO (NCT07454174)
- Testing
- Ren-Nu and KetoCitra
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Richard Fatica
Autosomal Dominant Polycystic Kidney
GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GBP-213 in patients with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT07891364
- Testing
- GBP-213
- Where
- China
- Volunteers
- 24 people
- Sponsor
- RenJi Hospital
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease
The primary aim of this observational exploratory study is to develop AI-based image processing methods to advance the characterization of Polycystic Kidney Disease using medical images and associated clinical data, including: 1.
- Trial name
- AI4PKD (NCT06688981)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Polycystic Kidney, Autosomal Dominant
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria.
- Trial name
- STOP-PKD (NCT07280585)
- Testing
- Dapagliflozin 10 mg
- Where
- 30 sites in Austria, Germany and 2 more
- Volunteers
- 420 people
- Sponsor
- University of Cologne
ADPKD (Autosomal Dominant Polycystic Kidney Disease), Renal Edema
A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic Impairment
The primary purpose of this study is to evaluate the plasma PK of JMKX003142 following a single dose in participants with mild and moderate hepatic impairment compared to matched healthy participants with normal hepatic function.
- Trial name
- NCT07909070
- Testing
- JMKX003142
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jemincare
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Dietary Modulation of Urinary MCP-1 in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and declining kidney function. Inflammatory pathways, including those mediated by monocyte chemoattractant protein-1 (MCP-1), are…
- Trial name
- NCT07651397
- Testing
- Carbohydrate Restricted, Plant Dominant Diet, usual diet
- Volunteers
- 36 people
- Sponsor
- Assaf-Harofeh Medical Center
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Robotic vs Open Nephrectomy for ADPKD
The goal of this observational prospective cohort study is to evaluate the feasibility, safety, and postoperative outcomes of robotic-assisted unilateral native nephrectomy using the Medtronic Hugo™ RAS system compared with the…
- Trial name
- ADPKDR-O (NCT07355114)
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- University of Bologna
Autosomal Dominant Polycystic Kidney
Outcome of ADPKD With Octreotide LAR
In this observational, retrospective study we will primarily aim at evaluating the independent role of baseline clinical and laboratory parameters, including TKV, in the prediction of long term chronic GFR decline and other…
- Trial name
- ADPKD648 (NCT06193616)
- Testing
- Octreotide
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys.
- Trial name
- ANCHOR (NCT06902558)
- Testing
- ABBV-CLS-628
- Where
- 91 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Calico Life Sciences LLC
Polycystic Kidney Diseases
Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related complications are common…
- Trial name
- COMPLIK (NCT06036992)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Brest
ADPKD, Autosomal Dominant Polycystic Kidney
Statin Therapy in Patients With Early Stage ADPKD
This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT03273413
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Colorado, Denver
AKI, CKD
Genetics in the Progression of Nephropathies
This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to: AKI CKD Hypertension ADPKD CKD-MBD Patients with decompensated heart failure undergoing either…
- Conditions
- AKI, CKD, Ckd-Mbd, CKD (Chronic Kidney Disease) Stage 5D
- Trial name
- NCT06416761
- Testing
- genetic polymorphisms
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- Ospedale San Raffaele
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug-drug interaction (DDI) potential of GV-100 following oral administration in healthy…
- Trial name
- NCT07788014
- Testing
- GV-100
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gilva Therapeutics Inc.
ADPKD
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function.
- Trial name
- HYDRO-PROTECT (NCT05373264)
- Testing
- Hydrochlorothiazide 25 mg
- Where
- 25 sites in Austria, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- University Medical Center Groningen
Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
Multicenter trial on the effect of the GnRH analogue leuprorelin on the growth of total liver volume in pre-menopausal women with very severe polycystic liver disease who, despite available therapy, experience growth and are…
- Trial name
- AGAINST-PLD (NCT05478083)
- Testing
- Leuprorelin
- Where
- 2 sites in Netherlands
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen